Why ManKind (MNKD) Stock Is Soaring Today

NEW YORK (TheStreet) -- ManKind (MNKD) shares are spiking, up 10.6% to $11.06, on Monday after the FDA approved the company's inhaled insulin drug Afrezza.

Wall Street analysts believe that the drug could generate peak yearly sales of $600 million for the company.

Must ReadWarren Buffett's 25 Favorite Stocks

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.


More from Markets

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI